Business Description
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
Business History
Price Overview
Last updated: Jun 27, 2026 11:02am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.14
Total Equity: $1.39B
Shares: 176,221,530
Total Debt: $1.01B
Cash: $781.08M
EBITDA: $147.30M
Total Debt: $1.01B
Cash: $781.08M
Revenue: $2.53B
Shares: 176,221,530
Revenue: $2.53B
Revenue: $2.53B
Revenue: $2.53B
Total Equity: $1.39B
Tax Rate: 14.9%
Equity: $1.39B
Total Debt: $1.01B
Cash: $781.08M
Current Liabilities: $404.74M
Long-Term Debt: $994.92M
Total Debt: $1.01B
Total Equity: $1.39B
Shares: 176,221,530
Shares: 176,221,530
CapEx: -$8.89M
Shares: 176,221,530
Stock Price: $8.39
Net Income: -$200.32M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.0B | $2.4B | $2.6B | $2.6B | $2.5B |
| Cost of Revenue | $650.3M | $744.0M | $760.0M | $751.3M | $771.6M |
| Gross Profit | $1.4B | $1.7B | $1.8B | $1.8B | $1.8B |
| Operating Expenses | $1.6B | $15.3B | $2.1B | $2.8B | $2.0B |
| Operating Income | -$265.6M | -$13.7B | -$248.6M | -$1.0B | -$263.0M |
| Net Income | -$428.8M | -$13.7B | -$220.4M | -$1.0B | -$200.3M |
| EBITDA | -$31.4M | -$7.5M | $43.6M | $31.7M | $147.3M |
| EPS | $-2.73 | $-84.60 | $-1.36 | $-5.87 | $-1.14 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $893.5M | $918.2M | $1.1B | $1.3B | $781.1M |
| Total Current Assets | $1.2B | $1.3B | $1.5B | $1.7B | $1.1B |
| Total Assets | $17.7B | $4.7B | $4.4B | $3.5B | $3.1B |
| Current Liabilities | $331.0M | $399.8M | $420.6M | $941.5M | $404.7M |
| Long-Term Debt | $1.2B | $1.5B | $1.5B | $991.4M | $994.9M |
| Total Liabilities | $1.7B | $2.4B | $2.1B | $2.0B | $1.7B |
| Total Equity | $16.0B | $2.3B | $2.3B | $1.5B | $1.4B |
| Retained Earnings | -$1.4B | -$15.0B | -$15.2B | -$16.2B | -$16.4B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $194.0M | $189.3M | $350.0M | $293.7M | $294.4M |
| Capital Expenditure | -$8.5M | -$16.5M | -$156.3M | -$10.8M | -$8.9M |
| Free Cash Flow | $185.5M | $172.8M | $193.7M | $282.9M | $285.5M |
| Acquisitions (net) | -$78.7M | $0 | $0 | $0 | -$81.9M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $160.2M | $24.7M | $205.5M | $174.7M | -$517.2M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 11:02am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$2.5B $2.5B – $2.6B
|
$2.6B $2.6B – $2.6B
|
$2.6B $2.6B – $2.7B
|
$2.8B $2.8B – $2.9B
|
| EBITDA |
$338.6M $327.9M – $348.0M
|
$343.5M $343.3M – $343.7M
|
$351.7M $344.3M – $357.6M
|
$376.9M $369.0M – $383.2M
|
| Net Income |
-$128.5M -$173.2M – -$85.2M
|
-$104.1M -$160.9M – $43.1M
|
-$33.9M -$34.6M – -$33.0M
|
$27.3M $26.6M – $27.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +18.4% | +8.1% | -1.3% | -1.5% |
| Gross Profit Growth | +20.3% | +10.8% | -1.3% | -3.3% |
| Operating Income Growth | -5,039.9% | +98.2% | -310.7% | +74.2% |
| Net Income Growth | -3,085.6% | +98.4% | -354.4% | +80.0% |
| EBITDA Growth | +76.0% | +678.7% | -27.3% | +364.3% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-10 | DIVITA CHARLES III | M-Exempt | 39,160.00 | $0.00 | $0 |
| 2026-06-11 | DIVITA CHARLES III | S-Sale | 18,074.00 | $6.94 | $125,470 |
| 2026-06-10 | DIVITA CHARLES III | M-Exempt | 3,642.00 | $0.00 | $0 |
| 2026-06-10 | DIVITA CHARLES III | M-Exempt | 39,160.00 | $0.00 | $0 |
| 2026-06-10 | DIVITA CHARLES III | M-Exempt | 3,642.00 | $0.00 | $0 |
| 2026-06-03 | Rodrigues Fernando M. | S-Sale | 9,572.00 | $7.40 | $70,833 |
| 2026-05-21 | Smith Mark Douglas | A-Award | 30,441.00 | $0.00 | $0 |
| 2026-05-21 | Paulus Kenneth H | A-Award | 30,441.00 | $0.00 | $0 |
| 2026-05-21 | Fenwick Sandra L | A-Award | 30,441.00 | $0.00 | $0 |
| 2026-05-20 | SHEDLARZ DAVID L | M-Exempt | 29,986.00 | $0.00 | $0 |
| 2026-05-21 | SHEDLARZ DAVID L | A-Award | 30,441.00 | $0.00 | $0 |
| 2026-05-20 | SHEDLARZ DAVID L | M-Exempt | 28,986.00 | $0.00 | $0 |
| 2026-05-20 | Jacobson Catherine | M-Exempt | 28,986.00 | $0.00 | $0 |
| 2026-05-21 | Jacobson Catherine | A-Award | 30,441.00 | $0.00 | $0 |
| 2026-05-20 | Jacobson Catherine | M-Exempt | 28,986.00 | $0.00 | $0 |
| 2026-05-20 | SNOW DAVID B JR | M-Exempt | 28,986.00 | $0.00 | $0 |
| 2026-05-21 | SNOW DAVID B JR | A-Award | 30,441.00 | $0.00 | $0 |
| 2026-05-20 | SNOW DAVID B JR | M-Exempt | 28,986.00 | $0.00 | $0 |
| 2026-04-01 | Catapano Joseph Ronald | M-Exempt | 2,083.00 | $0.00 | $0 |
| 2026-04-01 | Catapano Joseph Ronald | M-Exempt | 2,083.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).